Login
Navigate Fool.com
Will LLY beat
the market?

Eli Lilly & Co.

NYSE: LLY

Community Rating: 3 Stars: Appealing

59.77 0.35 (0.58%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $59.40
Previous Close $59.42
Daily Range $59.35 - $59.97
52-Week Range $47.53 - $60.46
Market Cap $66.9B
P/E Ratio 13.75
Dividend (Yield) $1.96 (3.3%)
Ex-Dividend Date
Dividend Pay Date
02/12/14
03/10/14
Volume 1,563,651
Average Daily Volume 4,834,193
Current FY EPS $2.80

How do you think LLY
will perform against the market?

Top LLY Bull/Bear Pitches

 

cibient (14.8)
Submitted May 26, 2011

5% divy, sustainable payout ratio (45% according to Yahoo! Finance), MFI stats from <a href="http://MagicDiligence.com">MagicDiligence.com</a>:<br /><br />Results for ticker 'LLY' (Eli Lilly and Compa … More

0 Replies Reply Report this Post
 

bobbyvee (< 20)
Submitted March 7, 2009

Pharaceuticals will suffer under this administration's plan for universal care

4 Replies Reply Report this Post

News & Commentary

The Biggest Biotech Wins of the Week

Find out which biotech and pharmaceutical companies posted the best clinical results for the week ending April 11.

Insider Stock Trading: Carl Icahn Buys Shares of Navistar International

Plus, purchases at Cerulean Pharmaceuticals, Alliqua, and Nature's Sunshine Products.

Eli Lilly's $3 Billion Mistake

A jury rules against Eli Lilly and partner Takeda with steep punative penalties

MannKind's Overly-Optimisitic Investors

Despite issues, over half of investors in a Motley Fool poll thought MannKind's inhaled insulin, Afrezza, would be approved this week.

Healthcare Stocks Posting Moderate Gains; Lilly, Partner File NDA for Combination Tablet for Diabete

Healthcare Stocks Posting Moderate Gains; Lilly, Partner File NDA for Combination Tablet for Diabetes

Sector Update: Healthcare

Is Teva Pharmaceutical Industries Ltd. Destined for Greatness?

Let's see what the numbers say about Teva (TEVA).

Stock Upgrades: Eli Lilly Coming Up Roses

Wall Street ratings agencies set the tone for today's stock market.

Can This Drug Be a Game Changer for Eli Lilly?

Eli Lilly's experimental breast cancer drug is reporting strong results in an early-stage trial. Here is what you need to know going forward.

2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals

Two clinical-stage cancer companies could provide market-beating returns for risk-tolerant investors.

See More LLY News...

Sector

Healthcare

Industry

Drugs

Eli Lilly & Co. (LLY) Description

The Company discovers, develops, manufactures and sells products in one of its business segment of pharmaceutical products to prevent and treat human diseases. Website: http://www.lilly.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks